I
Ionetix Corporation
Pioneering end-to-end radiopharmaceutical provider for pet imaging
About Ionetix Corporation
Ionetix Corporation is a radiopharmaceutical technology company that provides isotopes for both diagnostic imaging and therapeutic applications. The company was founded in 2009, commercializing technology originally developed at the MIT Plasma Science and Fusion Center. One of the founders identified is T. Timothy Antaya. The company is currently led by Chairman & CEO Kevin J. Cameron.
The firm's core business revolves around a vertically integrated model that includes the design, engineering, and manufacturing of its proprietary cyclotrons, isotope production, and end-to-end drug manufacturing and distribution. Ionetix's primary clients are healthcare providers and PET programs. The business model for its diagnostic product involves a turnkey solution where Ionetix covers the installation and operational costs of its cyclotrons on or near a hospital's campus, and clients pay on a per-dose basis. This approach aims to make critical cardiac PET imaging more accessible and affordable.
Ionetix has developed the ION-12SC, a compact, superconducting cyclotron for point-of-care production of PET radioisotopes. Its small footprint and lower cost of ownership are significant differentiators from conventional cyclotrons. This system is primarily used to produce Nitrogen-13 (N-13) Ammonia, an FDA-approved radiopharmaceutical for myocardial perfusion PET imaging, which helps in the diagnosis and management of coronary artery disease. The short half-life of N-13 Ammonia necessitates on-site production, which the ION-12SC enables.
Expanding beyond diagnostics, Ionetix has entered the therapeutic space, specifically focusing on Targeted Alpha Therapy (TAT), an emerging cancer treatment. This therapy uses molecules like antibodies or peptides to deliver alpha-emitting radionuclides directly to cancer cells, minimizing damage to surrounding healthy tissue. To support this, Ionetix has established a dedicated manufacturing center in Lansing, Michigan, equipped with a more powerful 30 MeV cyclotron to produce alpha isotopes. The company is focusing on producing Actinium-225 (Ac-225) and Astatine-211 (At-211), two isotopes with significant potential in TAT but which have faced supply chain challenges. In August 2024, the company announced a financing round with investors including Eli Lilly and Company and Tees River to expand its cyclotron network and scale the supply of these alpha-emitters.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 60
- Open positions
- 6
- Dealroom signal
- 34.0/100
- Industry
- Health, Energy
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Veterinary, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Big Data, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Apr 2026 | $30M | $120M | Undisclosed | ↗ |
| CONVERTIBLEOther financing | Aug 2024 | $10M | — | Eli Lilly | ↗ |
Growth signals
Latest recorded traffic for Ionetix Corporation is 3K monthly website visits, up 42.9% over the last three months. Ionetix Corporation's team declined 3.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ionetix Corporation in the Delhi Charter Township ecosystem
The Ionetix Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Eli Lilly
Series B and later1 investor entered at this stage
POINT Biopharma
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ionetix Corporation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ionetix Corporation’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









